SASKATOON, Saskatchewan, July 30, 2024--(BUSINESS WIRE)--ZYUS Life Sciences Corporation (the "Company") (TSX-V: ZYUS), a Canadian-based life sciences company focused on the development and commercialization of novel cannabinoid-based pharmaceutical drug candidates for pain management, is pleased to announce that its wholly owned subsidiary, ZYUS Life Sciences Inc., has received a No Objection Letter ("NOL") from Health Canada for a proof-of-concept ("POC") trial respecting its lead drug candidate, Trichomylin? softgel capsules.

The NOL signifies Health Canada's agreement that the safety information collected thus far regarding Trichomylin? softgel capsules supports progressing into a patient population. The POC trial aims to, among other things, assess the preliminary efficacy and feasibility of Trichomylin? softgel capsules in patients with advanced cancer and moderate to severe cancer-related pain and derisk ZYUS’ previously announced Phase 2 clinical trial.

About ZYUS Life Sciences Corporation

ZYUS (TSXV: ZYUS) is a life sciences company focused on the development and commercialization of novel cannabinoid-based pharmaceutical drug candidates for pain management. Through rigorous scientific exploration and clinical research, ZYUS aims to secure intellectual property protection, safeguarding its innovative therapies and bolstering shareholder value. ZYUS’ unwavering commitment extends to obtaining regulatory approval of non-opioid-based pharmaceutical solutions, in pursuit of transformational impact on patients’ lives. For additional information, visit www.zyus.com or follow us on X (formerly known as Twitter) @ZYUSCorp.

Cautionary Note Regarding Forward-Looking Statements

This news release contains "forward-looking information" within the meaning of applicable securities laws relating to the Company’s business, the Company’s ability to advance clinical research activities, obtain regulatory approval of cannabinoid-based pharmaceutical drug candidates and introduce products that act as alternatives to current pain management therapies such as opioids, and derisk the previously announced Phase 2 clinical trial of Trichomylin^? softgel capsules. Any such forward-looking statements may be identified by words such as "expects", "anticipates", "intends", "contemplates", "believes", "projects", "plans", "will" and similar expressions. Readers are cautioned not to place undue reliance on forward-looking statements. Statements about, among other things, the Company’s business, the Company’s ability to advance clinical research activities, obtain regulatory approval of cannabinoid-based pharmaceutical drug candidates, introduce products that act as alternatives to current pain management therapies such as opioids, and derisk the previously announced Phase 2 clinical trial of Trichomylin^? softgel capsules are all forward-looking information. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, there can be no assurance that the Company will be able to achieve these results. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances or actual results unless required by applicable law.